Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Medtronic
McKesson
Merck
Boehringer Ingelheim

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GEFITINIB

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Gefitinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00005806 Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed National Cancer Institute (NCI) Phase 1 1999-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have advanced non-small cell lung cancer.
NCT00005806 Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed Memorial Sloan Kettering Cancer Center Phase 1 1999-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have advanced non-small cell lung cancer.
NCT00006048 ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer Unknown status AstraZeneca Phase 3 2000-05-01 RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. ZD 1839 may interfere with the growth factor and stop the tumor from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether chemotherapy is more effective with or without ZD 1839 for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without ZD 1839 in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
NCT00006049 ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer Unknown status AstraZeneca Phase 3 2000-05-01 RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. ZD 1839 may interfere with the growth factor and stop the tumor from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combination chemotherapy is more effective with or without ZD 1839 for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without ZD 1839 in treating patients who have stage III or stage IV non-small cell lung cancer.
NCT00012337 ZD 1839 in Treating Patients With Metastatic Kidney Cancer Completed National Cancer Institute (NCI) Phase 2 2001-01-01 RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. Drugs such as ZD 1839 may interfere with the growth factors and cause tumor cells to die. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have metastatic kidney cancer.
NCT00012337 ZD 1839 in Treating Patients With Metastatic Kidney Cancer Completed Memorial Sloan Kettering Cancer Center Phase 2 2001-01-01 RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. Drugs such as ZD 1839 may interfere with the growth factors and cause tumor cells to die. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have metastatic kidney cancer.
NCT00014144 S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract Completed National Cancer Institute (NCI) Phase 2 2001-02-01 RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of cancer of the urinary tract. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have advanced cancer of the urinary tract.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Gefitinib

Condition Name

Condition Name for Gefitinib
Intervention Trials
Non-small Cell Lung Cancer 51
Lung Cancer 38
Non Small Cell Lung Cancer 23
Breast Cancer 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Gefitinib
Intervention Trials
Carcinoma, Non-Small-Cell Lung 187
Lung Neoplasms 158
Adenocarcinoma 27
Carcinoma 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Gefitinib

Trials by Country

Trials by Country for Gefitinib
Location Trials
United States 488
China 120
Japan 75
Korea, Republic of 64
Italy 64
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Gefitinib
Location Trials
New York 41
Texas 30
California 29
Massachusetts 26
Pennsylvania 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Gefitinib

Clinical Trial Phase

Clinical Trial Phase for Gefitinib
Clinical Trial Phase Trials
Phase 4 9
Phase 3 48
Phase 2/Phase 3 9
[disabled in preview] 297
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Gefitinib
Clinical Trial Phase Trials
Completed 175
Recruiting 54
Unknown status 42
[disabled in preview] 86
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Gefitinib

Sponsor Name

Sponsor Name for Gefitinib
Sponsor Trials
AstraZeneca 88
National Cancer Institute (NCI) 65
Sun Yat-sen University 13
[disabled in preview] 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Gefitinib
Sponsor Trials
Other 374
Industry 177
NIH 68
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Medtronic
Colorcon
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.